Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)

MA Gómez, A Navas, MD Prieto… - Clinical Infectious …, 2021 - academic.oup.com
Background Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in
our understanding of the determinants of therapeutic outcome impede optimization of …
被引用次数：5 相关文章

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)

MA Gómez, A Navas, MD Prieto… - … publication of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in
our understanding of the determinants of therapeutic outcome impede optimization of …
[HTML] nih.gov

[HTML][HTML] Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)

MA Gómez, A Navas, MD Prieto… - … Diseases: An Official …, 2021 - ncbi.nlm.nih.gov
Background Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in
our understanding of the determinants of therapeutic outcome impede optimization of …

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia).

MA Gómez, A Navas, MD Prieto… - Clinical Infectious …, 2021 - search.ebscohost.com
Background Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in
our understanding of the determinants of therapeutic outcome impede optimization of …
[PDF] oup.com

[PDF][PDF] Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)

MA Gómez, A Navas, MD Prieto… - Clinical Infectious …, 2021 - academic.oup.com
Background Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in
our understanding of the determinants of therapeutic outcome impede optimization of …

Immuno-pharmacokinetics of meglumine antimoniate in patients with cutaneous leishmaniasis caused by Leishmania (Viannia).

MA Gómez, A Navas, MD Prieto, L Giraldo-Parra… - 2020 - cabidigitallibrary.org
Background: Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in
our understanding of the determinants of therapeutic outcome impede optimization of …

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia).

MA Gómez, A Navas, MD Prieto… - … Diseases: an Official …, 2021 - europepmc.org
Background Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in
our understanding of the determinants of therapeutic outcome impede optimization of …